Clinical Trial Update: A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients. [Phase 4]

View source ↗

Summary

This Phase 4, multicenter, open-label randomized trial evaluated pamidronate for preventing bone loss in de novo renal transplant patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Pamidronate (pamidronate disodium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Bone Loss | Phase 4 | Status: COMPLETED